Antiseizure drugs (ASDs) are commonly used to treat a wide range of nonepileptic conditions, including
pain. In this context, the
analgesic effect of four
pyrrolidine-2,5-dione derivatives (compounds 3, 4, 6, and 9), with previously confirmed
anticonvulsant and preliminary antinociceptive activity, was assessed in established
pain models. Consequently, antinociceptive activity was examined in a mouse model of tonic
pain (the
formalin test). In turn, antiallodynic and antihyperalgesic activity were examined in the
oxaliplatin-induced model of
peripheral neuropathy as well as in the
streptozotocin-induced model of
painful diabetic neuropathy in mice. In order to assess potential
sedative properties (
drug safety evaluation), the influence on locomotor activity was also investigated. As a result, three compounds, namely 3, 6, and 9, demonstrated a significant antinociceptive effect in the
formalin-induced model of tonic
pain. Furthermore, these substances also revealed antiallodynic properties in the model of
oxaliplatin-induced
peripheral neuropathy, while compound 3 attenuated
tactile allodynia in the model of diabetic
streptozotocin-induced
peripheral neuropathy. Apart from favorable
analgesic properties, the most active compound 3 did not induce any
sedative effects at the active dose of 30 mg/kg after intraperitoneal (i.p.) injection.